ACRES Commercial Realty Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ACR research report →
Range $17 – $17
Price Chart
About the company
ACRES Commercial Realty Corp. (ACR) functions as a real estate investment trust (REIT) based in Uniondale, New York, having been established in 2005. The firm's primary objective is to generate, own, and administer various debt instruments related to commercial real estate, including mortgage loans, throughout the United States.
- CEO
- Mark Steven Fogel
- IPO
- 2006
- Employees
- 4
- HQ
- Uniondale, NY, US
Get TickerSpark's AI analysis on ACR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $57.76M
- P/E
- -1.06
- Fwd P/E
- 5.40
- PEG
- -0.00
- P/S
- 0.32
- P/B
- 0.16
- EV/EBITDA
- 43.50
- Div Yield
- 0.00%
- Gross Margin
- 70.81%
- Op Margin
- 42.07%
- Net Margin
- -28.34%
- ROE
- -11.72%
- ROIC
- 1.68%
Latest fiscal year · YoY change
- Revenue
- $165.90M+98.7%
- Gross Profit
- $159.34M+335.4%
- Op Income
- $102.39M
- Net Income
- $21.32M-27.2%
- EPS
- $0.03-97.2%
- OCF Growth
- -78.8%
- FCF Growth
- -79.7%
- 52W High
- $24.61
- 52W Low
- $7.76
- 50D MA
- $11.27
- 200D MA
- $16.41
- Beta
- 1.10
- RSI (14)
- 31
- Avg Volume
- 48.96K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
ACRES Commercial Realty reported a noisy transition quarter after its merger/internalization, with portfolio credit holding steady and management pointing to a longer-term path to higher run-rate earnings through asset management, insurance, and balance-sheet optimization.· November 5, 2026
- Merger and internalization closed on August 6, and management said the transaction should support earnings growth while reducing leverage.
- Quarter-end loan portfolio was $2.1 billion across 56 loans; credit was described as stable with a weighted-average risk rating of 2.6.
- GAAP net loss allocable to common was $5.16 per diluted share, and EAD loss was $2.64 per diluted share, but management said the quarter included $38.3 million of one-time transaction-related accounting charges.
- CECL reserve rose to $29.4 million, or 137 basis points of the loan portfolio, from $21.1 million last quarter, mainly due to macroeconomic forecast inputs.
- Management reiterated a long-term objective of $2 to $3 per share of run-rate EAD earnings and said stabilized G&A should land between $29 million and $32 million.
ACRES reported GAAP net loss allocable to common shares of $5.16 per diluted share and EAD loss of $2.64 per diluted share. Book value per share was $16.81. The commercial real estate loan portfolio ended the quarter at $2.1 billion across 56 loans, with 99.5% floating rate and a weighted-average spread of 321 basis points over SOFR. During the quarter, the company funded $45 million and received $36 million of payoffs, for a net portfolio increase of $9 million. CECL reserve was $29.4 million, or 137 basis points of the loan portfolio, versus $21.1 million last quarter. Management said the quarter included $38.3 million of one-time accounting charges, including $13.7 million of non-cash charges. Looking ahead, management did not provide formal next-quarter or full-year financial guidance, but reiterated a long-term objective of $2 to $3 per share of run-rate EAD earnings and said stabilized G&A should be $29 million to $32 million.
Andrew Fentress framed the merger/internalization as a strategic reset designed to create a public company that can grow earnings while reducing leverage. He emphasized three business lines now under the umbrella: principal investing, investment management, and insurance, and said the company will use those platforms to diversify revenue over time. His tone was optimistic and long-term focused, with repeated emphasis on alignment with shareholders, disciplined capital allocation, and a stated goal of paying dividends only when earned.
Mark Fogel focused on portfolio stability and the mechanics of the quarter. He said the loan book was $2.1 billion across 56 loans, 99.5% floating rate, with a 321 basis point spread over SOFR; the weighted-average risk rating was unchanged at 2.6. He also highlighted $29.4 million of CECL reserve, $8.4 million of depreciation and amortization, and $38.3 million of one-time transaction-related accounting charges, while noting corporate debt was refinanced with maturities extended to 2031 and beyond and liabilities now have a 10.5-year WAL. He also said the company raised about $50 million from preferred issuance and has a $5 million repurchase authorization.
Analysts pressed for clarity on the post-deal run rate for the investment management business, the REO portfolio, and how to bridge to the company’s $2 to $3 per share EAD objective. Management said it was not giving specific guidance on AUM-related metrics yet, but expects to provide quarterly updates and believes the investment management business is operating at peak AUM relative to its history. On REOs, management said some assets are turning the corner, including a Chicago property converted to multifamily that should be leased to market occupancy by Q3 2027 and may be monetized in the coming year. They also addressed capital structure questions by saying there is about $300 million in common equity, about $230 million in preferred equity, and about $500 million in non-controlling interests, all described as leverageable.
The company said the transaction simplifies the story and creates more diversified earnings streams through investment management and insurance, while also reducing leverage over time. Management sounded constructive on CRE fundamentals, said supply is declining, and argued that the pipeline of new lending opportunities and financing markets are both favorable. They also pointed to improving REO performance and said one converted property should help demonstrate recoveries and potential upside.
The quarter was weighed down by large transaction-related accounting noise, including $38.3 million of one-time charges, and the company reported a GAAP loss and an EAD loss. CECL reserves increased meaningfully to $29.4 million from $21.1 million, with management citing macroeconomic forecast pressure on the sector. Analysts also pushed on whether REOs are becoming an earnings drag and on how the company will translate the new structure into the stated $2 to $3 per share EAD target, with management declining to give near-term metric guidance.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 89.2%
- Shares Outstanding
- 7.13M
- Float Shares
- 6.36M
of shares held by institutions
67 13F filers
Buy/sell ratio 1.15. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Eagle Point Credit Management LLC | 1.18M | 0 |
| Blackrock, Inc. | 383.39K | ▼ 68.94K |
| Vanguard Group Inc | 378.26K | ▼ 5.44K |
| Vanguard Capital Management LLC | 279.50K | ▲ 27.30K |
| Geode Capital Management, LLC | 155.09K | ▲ 15.04K |
| Nokomis Capital, L.L.C. | 131.36K | ▼ 14.41K |
| Mink Brook Asset Management LLC | 101.53K | ▼ 84 |
| State Street Corp | 89.07K | ▼ 474 |
| Acadian Asset Management LLC | 64.57K | ▼ 56.34K |
| Vanguard Fiduciary Trust Co | 52.33K | ▲ 15.97K |
| Northern Trust Corp | 49.83K | ▲ 5.19K |
| Vanguard Portfolio Management LLC | 39.16K | ▲ 671 |
Held by 85 ETFs
Biggest fund positions in ACR by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 10, 26 | BRYANT DAVID J | sell | 1,440 |
| Aug 6, 26 | Fogel Mark S | other | 1,440,552 |
| Aug 6, 26 | Kilpatrick Linda M | other | 3,928 |
| Aug 6, 26 | NEFF P SHERRILL | other | 4,280 |
| Aug 6, 26 | KESSLER STEVEN J | other | 2,568 |
| Aug 6, 26 | Jesberger Jaclyn | other | 343,856 |
| Aug 6, 26 | Ickowicz Gary | other | 2,568 |
| Aug 6, 26 | Edwards Karen K | other | 2,568 |
| Aug 6, 26 | Blackwell Eldron C | other | 7,856 |
| Aug 6, 26 | Brengel Kyle K. | other | 309,675 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ACR coverage
Recent articles, reports, and earnings notes.
No research on ACR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ACR report →Fate Therapeutics Presents New FT819 Data at ACR Convergence 2026 Highlighting Meaningful Clinical Responses in Lupus Without the Use of Conditioning Chemotherapy
globenewswire.com · Nov 10
Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2026 on the Potential of MRT-8102 in Gout
globenewswire.com · Nov 9
ACR 2026: Dapirolizumab Pegol Associated with Greater Treatment Response Rates Versus Placebo in SLE Using Novel Treatment Response Measure
globenewswire.com · Nov 9
IMP761 Late-Breaking Abstract at ACR Convergence 2026 Highlights Statistically Significant & Exposure-Dependent Inhibition of T-Cell-Driven Immune Responses
globenewswire.com · Nov 8
Velinotamig, a BCMAxCD3 T Cell Engager, Achieves Complete Renal Responses and Significantly Reduces Disease Activity in Systemic Lupus Erythematosus in Data Presented at ACR Convergence 2026
globenewswire.com · Nov 8
Cabaletta Bio Presents New Rese-cel Phase 1/2 Clinical Data at ACR Convergence 2026 Featuring Immunomodulator-Free Durability and Favorable Benefit-Risk Profile Across Autoimmune Diseases
globenewswire.com · Nov 8
ACRES Commercial Realty Corp. (ACR) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 7
argenx Presents Phase 3 ALKIVIA Data at ACR Convergence 2026 Showing Rapid and Sustained Improvement with Efgartigimod in Autoimmune Myositis
globenewswire.com · Nov 7
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.